Albers Jeffrey W.'s Form 4 filing
Blueprint Medicines Corp (BPMC) · filed Mar 26, 2024
- Accession no.
- 0001415889-24-009169
- Filed
- Mar 26, 2024
- Trade date
- Mar 7, 2024
- Filing delay
- 19 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $1.00M. It was filed 19 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Albers Jeffrey W.CIK 0001638474 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | Common Stock | SSaleDisposed | −11,033 | $90.69 | −$1,000,582.77 | 165,017 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.